Epidemiological reports on lymphomas often begin, and sometimes end, by stating that little is known about the causes of the condition(s) under study. This is slowly changing as information on the pathological diversity of subtypes accumulates. This review examines the epidemiology of lymphomas, focusing on the impact of the latest World Health Organization (WHO) classification. Use of appropriate disease classifications is critical to the research process, but many studies conducted in previous decades have been hampered by the need to aggregate data into the broad lymphoma groupings of Hodgkin and non-Hodgkin, either because primary source information was recorded in that way, or because diagnostic standards were inconsistently applied. Population-based data on age and gender are presented using the latest WHO classification, revealing considerable subtype heterogeneity. Aetiological factors highlighted include the unexplained male bias that is strikingly evident for many subtypes across all ages, and the relationship with autoimmune disease, which, although often associated with increased lymphoma risk, is generally more common in females. This is an exciting time for epidemiological research into haematological malignancies, where the application of modern disease classifications is beginning to discriminate between subtypes revealing features that future aetiological hypotheses should seek to address.
Introduction
Epidemiology is the basic quantitative science of public health, and as such is concerned with the distribution, determinants, treatment, management and potential control of disease. Concentrating on the first two of these, this article aims to review the epidemiology of the lymphomas -a heterogeneous group of malignancies that are estimated to account for approximately 3-4% of cancers worldwide ( Figure 1 ). 1 Before consideration of their epidemiology in any depth, the issue of disease classification -which permeates the discussion throughout -is touched on below. In order to originate and test hypotheses about pathogenesis, it is vitally important to accurately describe and understand underlying disease patterns. 2 Implicit in this is the need to use appropriate disease classifications, and it is this requirement that continues to hamper epidemiological research into lymphoid malignancies. In short, the classification of haematological malignancies has changed markedly over recent decades, and will continue to do so as new diagnostic methods and techniques are developed. 3 In 2001, the World Health Organization (WHO) produced, for the first time, a consensus classification that defined malignancies of the haematopoietic and lymphoid systems in terms of immunophenotype, genetic abnormalities and clinical features. 4 Until then, competing classifications had often made meaningful comparison of results between epidemiological studies virtually impossible.
Although the WHO's 2001 classification was adopted into clinical practice almost uniformly around the world, it did not have an immediate effect on population-based epidemiological research. This is because, unlike many other cancers, haematological neoplasms are diagnosed with the use of multiple parameters, including a combination of histology, cytology, immunophenotyping, cytogenetics, imaging and clinical data. Furthermore, in practice, even within some of the best defined WHO categories, there is a need to qualify the final diagnosis even further with the use of additional clinical and biological prognostic factors before valid outcome comparisons can be made. 5, 6 This range and depth of data are difficult for cancer registries and other researchers to access systematically, forming a barrier both to complete ascertainment and to the collection of diagnostic data at the level of detail required for systematic implementation of the latest WHO classification.
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Descriptive epidemiology
Although cancer registration has a long history in many countries, particularly those in the more affluent regions of the world, nearly 80% of the world's population are not covered by such systems. 7 Nonetheless, with a view to characterizing the global burden of disease, the WHO's International Agency for Research on Cancer (IARC) routinely uses the available data to estimate worldwide cancer incidence and mortality levels. 1 Misdiagnosis and undernumeration are, however, recognized problems for haematological cancers. The acute and rapidly fatal presentation of Males A some lead to undernumeration in countries with less well-developed health service infrastructures; and the intermittent and non-specific nature of symptoms associated with others 8, 9 poses problems even in countries with well-developed health service systems and cancer registration processes. In addition, population-based data continue to be reported in the broad anatomy-based categories of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), myeloma and leukaemia, 1, [10] [11] [12] [13] as, for the reasons outlined in the Introduction, the laboratory data required to classify haematological malignancies appropriately are hard for cancer registries to access in a timely and systematic fashion.
international patterns
Incidence figures from the IARC's most recent series of estimates are presented in Figures 1-3 . Of the 12.68 million new cancer cases estimated to have occurred around the world in 2008, 6.64 million were in men and 6.04 million in women -haematological malignancies comprising 7.5% of cancers in males and 6.4% in females. In both sexes, lymphomas were estimated to have accounted for approximately half of all newly diagnosed haematological neoplasms ( Figure 1 ).
The age-standardized lymphoma rates (NHL + HL) for both sexes combined are globally distributed in Figure 2 . With one or two exceptions, the geographical pattern is dominated by the high rates in the more economically developed regions of the world. This is seen more clearly in Figure 3 , which shows the estimated regional rates and numbers of cases of NHL and HL separately for men and women (http://globo can.iarc.fr/). Under half of all NHL and HL diagnoses occurred in the three regions with the highest ratesNorth America, Europe and Oceania -largely reflecting the underlying world population distribution. The most striking disparity is seen for Asia, which has the lowest rates but more than one-third of all estimated cases.
variations with age and sex
That lymphoid malignancies are generally more common in men than in women is evident in Figure 3 . For both NHL and HL, the age-standardized rates and numbers are consistently higher for males than for females, the differences tending to be slightly more pronounced in less developed regions of the world (http://globocan.iarc.fr/). The sex rate ratios (male ⁄ female) for HL, for example, ranged from 1.8 and 1.6 in Africa and Asia through to 1.2 and 1.1 in North America and Europe. Whether or not this gradation reflects genuine differences or biases within the data cannot be ascertained from the available information. The NHL and HL age-specific incidence patterns seen in developed regions of the world are broadly similar to the UK data, shown in Figure 4 . The relationship with age is, however, quite different for NHL and HL. For NHL, the age-specific male and female rates increase with increasing age, the divergence between the male and female rates becoming progressively more marked as age increases. By contrast, the HL incidence distribution has two peaks -one in young adults and one in the elderly. There is a pronounced male excess in the adult years, but with a slightly earlier peak and deeper trough in females, the shapes of two curves are slightly different. These patterns reflect the fact that HL comprises several disease entities, each with its own descriptive features. 3, 14 The impact of such differences on basic descriptive age and sex patterns can be seen more clearly in Figures 5-7 Figure 5 , beginning with the B-cell NHLs, moving clockwise thorough the T-cell NHLs, and ending with the HLs. 3 Diffuse-large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL) dominate, accounting for more than 70% of the total. The corresponding boxand-whisker age distributions are shown in Figure 6 , and the sex-specific incidence rate ratios (male rate ⁄ female rate), together with their standard errors, in Figure 7 .
Although most patients with B-cell NHLs have a median diagnostic age over 70 years, a significant minority tend to be diagnosed at younger ages -those with FLs, Burkitt lymphomas and mediastinal lymphomas having median ages of 65, 52 and 36 years respectively. Furthermore, there are much broader age ranges for some lymphomas than for others -with no patients diagnosed before the age of 48 years and a median of 74 years, the age distribution of mantle cell lymphoma shows the least variation. By contrast, with a median diagnostic age approaching 71 years, but with several sporadic paediatric cases, DLBCL covers the largest age range -the scatter of outliers at younger ages being indicative, perhaps, of diagnostic heterogeneity within this subtype category. Overall, Tcell NHLs tend to be diagnosed at younger ages, but in common with the B-cell form of disease, there is considerable subtype heterogeneity -the tight age band for enteropathy type T-cell lymphoma contrasting with that seen for anaplastic large T-cell lymphoma, for example. Finally, with a pronounced paediatric component, HL tends to be diagnosed earlier still, but again there are differences between the subtypes -the median ages within the classical HL (CHL) category, for example, ranging from 37 years for nodular sclerosis CHL to 60 years for mixed cellularity CHL ( Figure 6 ). That males are far more likely to develop lymphoma than females is conspicuously clear in Figure 7 -but it is also evident that the gender disparity is much greater for some subtypes and almost absent for others. Among B-cell NHLs, roughly equal numbers of males and females were diagnosed with FL and with extranodal MZL, but the sex rate ratio for all other B-cell lymphomas shows a male bias -the most striking being for Burkitt lymphoma, which, in these and other series, is at least three times as likely to be diagnosed in males as in females. T-cell NHLs and HLs also exhibit a male bias, but again there is considerable subtype heterogeneity, with angioimmunoblastic T-cell lymphoma running counter to the trend by being more common in women ( Figure 7) . The wide diversity of descriptive patterns shown in Figures 6 and 7 are indicative of different subtype aetiologies, which many new and ongoing epidemiological studies are aiming to address. However, the continued application of site-based classification systems for routine cancer registration severely limits the use of such data in epidemiological studies. Hopefully, in the future, new insights into lymphoma epidemiology will emerge as the WHO classification becomes more widely applied.
changes over time
Monitoring disease trends over time is fundamental to descriptive epidemiology, such analyses often yielding important aetiological clues. Indeed, there are many examples in the field of cancer epidemiology where this has been the case, particularly in relation to the identification of hazardous occupational and environmental exposures. 2 In this context, the temporal changes reported for NHL in recent decades are unquestionably dramatic, as can be seen from Figure 8 , which shows the estimated age-adjusted incidence rates from the Surveillance, Epidemiology and End Results Program in the USA (http://www.seer.cancer.gov). The sharp increase seen for NHL between the 1970s and 1990s was reported in many developed countries, and naturally captured both scientific and public attention at the time (Figure 8 ). In males, the doubling of the NHL rate over a 20-year period is particularly striking, and contrasts with the modest fall in HL seen in males over the same time period. Although it is generally recognized that changing diagnostic practices are almost certainly involved in these trends, there remains debate about whether such changes could have been responsible for all, or only part, of the increase in NHL. 2, [16] [17] [18] In this context, the potential aetiological role of human immunodeficiency virus (HIV), as well as of other viruses and exposures, has attracted considerable attention; and these factors are discussed in more detail in the section on causes below.
The rate of change in NHL slowed in the USA towards the end of the twentieth century, and similar plateauing has now been reported for other developed regions of the world. 18, 19 Taken at face value, this would seem to support the notion that changes in disease detection, diagnostic practice and cancer registration procedures are all likely to have contributed to the increase seen over the 1970s and 1990s. Indeed, the UK Department of Health noted in 2003 that 'There are no precise and reliable figures for incidence and survival rates for the different forms of haematological cancer in England and Wales. Whilst the Office for National Statistics (ONS) and Wales Cancer Intelligence and Surveillance Unit do publish descriptive statistics, there are many problems with these figures. For example, there is evidence that many cases are never reported to cancer registries, so the actual number of patients could be substantially higher than national figures suggest.' 20 Likewise, a recent report examining incidence and survival trends across Europe concluded that 'the evolving classification and poor standardization of data collected on hematological malignancies vitiate the comparisons of disease incidence and survival over time and across regions'. 21 Importantly, with respect to the examination of future time-trends, the role of changing diagnostic practice will undoubtedly remain challenging to evaluate, as haematological oncology is changing rapidly, with new approaches to treatment and diagnosis continually emerging as diverse patient pathways evolve. In this regard, the use of more reliable and sensitive diagnostic techniques continues to lower the threshold of disease detection -the ability of flow cytometry to detect small populations of abnormal cells, for example, as well as the introduction of the polymerase chain reaction, allowing the detection of disease at a molecular level. Hence, proportionately more of the patients diagnosed today have indolent or asymptomatic disease, 6, 15 and it remains possible that the increasing numbers of registrations may be attributable, at least in part, to the recognition of new group(s) of patients that would not have been diagnosed in previous decades.
Aetiology
As discussed above, the use of appropriate disease classifications is critical to the research process, and many studies conducted in previous decades have been hampered by the need to aggregate their data into the broad groupings of NHL or HL, either because primary source information was recorded in that way, or because diagnostic standards were inconsistently applied. Hence, given the underlying variations in pathologies and prognosis, it is perhaps not surprising that many epidemiological reports on lymphomas often begin, and sometimes end, by stating that little is known about the causes of the condition(s) under study. However, this is beginning to change, as evidence about the pathological and clinical diversity of lymphoma subtypes continues to accumulate, revealing not only descriptive differences such as those outlined in the previous section, but also other potentially immune-mediated associations. In this regard, it is generally agreed that immune dysregulation plays a pivotal role in lymphogenesis, and most epidemiological research has concentrated on factors and exposures that interact with the immune system. infection It has been known for some time that immunodeficiency syndromes (inherited and acquired) predispose towards lymphoproliferative disorders, and in this regard, the strong association between HIV ⁄ acquired immunodeficiency syndrome (AIDS) and several B-cell lymphomas has been examined in numerous studiesthe increased risks reported range from 10-fold to 300-fold, the highest risks generally been observed for the more aggressive NHL subtypes and the lowest for the HLs. 22, 23 Unsurprisingly, the potential role of the HIV ⁄ AIDS epidemic was one of the factors evaluated in the context of the striking rise in NHL observed in the 1970s-1990s discussed above. NHL rates had, however, begun rise before the onset of the HIV ⁄ AIDS epidemic in the 1980s (Figure 8) , and even now the contribution of HIV ⁄ AIDS to the totality of lymphomas diagnosed in developed countries remains comparatively small.
In addition to HIV, a number of other viruses have been suggested to impact on lymphoma risk, albeit by different mechanisms. The most accepted viral associations are those with human T-cell leukaemia virus type 1 (HTLV-1) and the two herpesviruses, EpsteinBarr virus (EBV) and human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma herpesvirus. Infection with HTLV-1 is a necessary but not sufficient cause of adult T-cell leukaemia ⁄ lymphoma (ATLL), with ATLL developing in approximately 3% of those infected. ATLL principally occurs in areas where HTLV-1 is endemic, including Japan, the Caribbean and parts of Central Africa; and, like most other lymphomas, it is more common in males than in females. 3, 22, 24, 25 In contrast to the specific nature of the HTLV-1-ATLL association, the globally ubiquitous EBV features in several lymphoma subtypes, including Burkitt lymphoma and CHL, as well as those occurring in immunosuppressed individuals. EBV is invariably associated with the endemic form of Burkitt lymphoma that occurs in equatorial Africa and New Guinea, where, with a median age of around 7 years and a male ⁄ female ratio of 2:1, it is the commonest childhood malignancy. However, as can be seen from Figure 6 , the median age at onset of the comparatively rare sporadic form of Burkitt lymphoma seen in other areas of the world is much later, and the male predominance is much greater (Figure 7) . In contrast to the situation with endemic Burkitt lymphoma, EBV is associated with approximately one-third of all sporadic cases, and the role of EBV in these tumours is a continuing area of research. 3, 24, 26 Likewise, the significance of the well-established association between EBV and CHL, observed most frequently in children and the elderly, and found in approximately one-third of all cases in resource-rich countries -and even more commonly in less affluent parts of the world -remains an area of current investigation. 3, 24, 25, 27 HHV-8 has been found in several comparatively rare tumour subtypes, where it sometimes occurs with EBV. 25 The nature of this association, and those of a number of other viruses, including hepatitis C virus, 25, 28 are topics of ongoing research.
Bacterial infection resulting in chronic inflammation has been consistently linked with a marked increase in risk for some NHL subtypes -one of the best known associations is that between Helicobacter pylori and gastric mucosa-associated lymphoid tissue (MALT) extranodal MZL, the presence of the bacteria increasing lymphoma risk approximately sixfold. 3, 29, 30 As with the viral associations (e.g. HTLV-1 and ATLL), bacterial infection very often occurs many years before MALT lymphoma development, the median age of diagnosis of all extranodal MZLs combined in the HMRN series being just under 70 years ( Figure 6 ), with no obvious sex bias (Figure 7 ). H. pylori infection generally occurs in childhood, the prevalence being highest in developing countries and falling as socio-economic status rises. 31 In the future, the introduction of effective H. pylori treatments, coupled with increasing affluence in developed regions of the world, may well lead to a reduction in the incidence of H. pylori-positive gastric MZLs. 32 Interestingly, detailed analysis of medical records collected in a UK case-control study revealed significant increases in the frequency of non-specific infectious illness episodes more than 10 years before the diagnosis of CHL, but not of DLBCL and FL. 33, 34 Whether or not the excess seen for CHL was a consequence of an underlying immune abnormality, or whether infection played a causal role, could not be determined from the available data.
autoimmune disease
Several well-documented links between autoimmune disease-based chronic inflammation and MALT lymphoma are also recognized, two of the strongest and most well described being that between Hashimoto thyroiditis and thyroid lymphoma, and that between Sjögren's syndrome and salivary gland lymphoma. 3, [35] [36] [37] Consistent associations have also been reported for other chronic inflammatory rheumatic diseases, e.g. rheumatoid arthritis and systemic lupus erythematosus, with both MZLs and DLBCLs, 35, 38, 39 and for gastrointestinal inflammatory autoimmune conditions, such as coeliac disease and Crohn's disease, with the T-cell lymphomas. 35, 36, 40 Indeed, evidence linking lymphoproliferative disorders with autoimmunity continues to accumulate, the strongest associations being seen for MZLs, DLBCLs and T-cell lymphomas, 35, 36, 41 and the weakest for the relatively indolent FL. 36, 41, 42 Associations between chronic inflammatory rheumatic diseases and CHL, but not nodular sclerosis HL, have also been reported. 35, 37 Taking the evidence as a whole, there is broad consensus that elucidating the mechanisms underpinning the link between autoimmune disease and the lymphomas could lead to fundamental insights into the biology of both groups of disorders, and there is considerable speculation in the literature about potential mechanisms. 38, [43] [44] [45] In this regard, routine examination of sex-specific associations could provide valuable information, as it has long been known that most autoimmune conditions are considerably more common in women than in men, [46] [47] [48] whereas the reverse is true for the majority of lymphoproliferative malignancies. 3, 11, 15 Furthermore, there are well-documented sex-specific variations in immune response that may well impact on the risk of having these diseases. [48] [49] [50] other factors
In addition to investigating associations with autoimmune and infectious conditions, the InterLymph consortium (http://epi.grants.cancer.gov/InterLymph/), which is a scientific forum for epidemiological research on lymphomas established in 2001, has reviewed and reported on several health-related states ⁄ events and environmental exposures. 51 So far, relatively few notable associations have been reported: no consistent effects have been seen for self-reported smoking, 52 alcohol 53 and obesity, 54 and marginally reduced risks have been observed for self-reported sun exposure 55 and history of atopic infections. 56 Finally, with respect to genetic susceptibility, increased risks were confirmed among those with a self-reported family history of haematological cancers, 57 and, perhaps more importantly, polymorphisms in two immune system-related genes have been identified with the candidate gene approach, associations being seen for both DLBCL and MZL.
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Conclusion This is an exciting time for epidemiological research into haematological malignancy, where the application of modern disease classifications is beginning to discriminate between subtypes revealing features that future aetiological hypotheses should seek to address.
